Education
About Us
Working with TipRanks
Follow Us
Xspray Pharma AB (SE:XSPRAY)
:XSPRAY
XSPRAY Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr23.00 - kr90.61
Previous CloseN/A
Volume2.99K
Average Volume (3M)20.74K
Market Cap
kr1.04B
Enterprise ValueN/A
Total Cash (Recent Filing)kr208.24M
Total Debt (Recent Filing)kr128.22M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding37,138,493
10 Day Avg. Volume19,047
30 Day Avg. Volume20,741
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)1.71
Price to Sales (P/S)0.00
P/FCF Ratio-3.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Xspray Pharma AB News
PremiumCompany Announcements
FDA Sets PDUFA Date for Xspray Pharma’s Dasynoc® Application
PremiumCompany Announcements
Xspray Pharma AB AGM Resolutions and Strategic Initiatives---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
99.97% Public Companies and
Individual Investors
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr23.00 and its highest was kr90.61 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr1.04B.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Aug 06, 2025 which is in 82 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on May 07, 2025. The company reported -kr1.139 earnings per share for the quarter, beating the consensus estimate of -kr1.806 by kr0.667.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 37,138,493 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -kr1.139 in its last earnings report, beating expectations of -kr1.806. Following the earnings report the stock price went up 7.062%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
---
Company Description
Xspray Pharma AB
Xspray Pharma AB (XSPRAY) is a Swedish pharmaceutical company that specializes in developing improved versions of already approved and marketed drugs. The company focuses on creating novel formulations using its proprietary HyNap technology platform, which enhances the solubility and absorption of drugs. Xspray Pharma primarily targets the oncology sector, aiming to provide competitive alternatives to existing cancer treatments with better efficacy and safety profiles.
---
Technical Analysis
Cantargia AB
―
IRLAB Therapeutics AB Class A
―
Saniona AB
―
Xbrane Biopharma AB
―
SynAct Pharma AB
―
---